Acquisition of Mersana Therapeutics N O V E M B E R 2 0 2 5 Day One's Mission Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life- threatening diseases Q&A Session All Participants 2 Confidential Information. For internal use only. Forward Looking Statements This communication contains forward-looking statements. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", ...

Core Viewpoint - The company has experienced significant stock price fluctuations, with a cumulative increase of over 20% in two consecutive trading days, indicating abnormal volatility [1] Financial Performance - The company's revenue for the years 2022 to 2025 was reported as follows: 330 million, 203 million, 341 million, and 144 million respectively [1] - The net profit figures for the same period were -212 million, -204 million, -266 million, and -66 million, indicating continuous losses [1] Acquisition Plans - The company plans to acquire 100% equity of Jiahe Jingwei, but the transaction is subject to approval and faces multiple risks related to approval and integration [1] Market Behavior - The current short-term stock price increase may be driven by irrational speculation, prompting a cautionary note for investors regarding potential risks [1]

Core Viewpoint - Hubei Huaron Holdings Co., Ltd. experienced a significant stock price fluctuation, with a cumulative increase of 12% over three consecutive trading days, indicating abnormal volatility [1] Group 1: Stock Performance - The stock price of Hubei Huaron Holdings has shown a cumulative increase of 12% over three trading days, which is classified as abnormal volatility [1] Group 2: Share Transfer Agreement - The controlling shareholder and its concerted parties signed a share transfer agreement with Bocheng Huineng to transfer 25.01% of shares for a consideration of 450.4129 million yuan [1] - The acquisition funds have not yet been secured, leading to uncertainties regarding the transaction [1] - The detailed equity change report has not been prepared, and no financial advisor has been appointed, further adding to the uncertainty of the acquisition [1] Group 3: Financial Performance and Risks - The company reported a negative net profit excluding non-recurring items for 2024, with expectations of continued losses in the first half of 2025 [1] - The stock has been subjected to delisting risk warnings, and if certain conditions are met next year, it may face financial delisting [1] - The company has advised investors to be cautious and to invest rationally [1]